Table 2 Disproportionality analysis for acute kidney injury associated with teicoplanin and diuretics.

From: Drug–drug interaction signals between loop diuretics and teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports

 

AKI

Without AKI

Crude ROR

95% CI

Adjusted ROR

95% CI

p-value

Loop diuretics

 TEIC

100

1338

2.34

1.91–2.87

2.37

1.93–2.91

 < 0.0001

 Loop diuretics

2386

29,727

2.52

2.41–2.63

1.87

1.78–1.97

 < 0.0001

 TEIC + loop diuretics

47

284

5.19

3.81–7.07

4.83

3.52–6.61

 < 0.0001

 Non-target drugs

20,392

639,340

1.00

–

1.00

–

–

Thiazide diuretics

 TEIC

146

1606

2.71

2.29–3.22

2.68

2.25–3.19

 < 0.0001

 Thiazide diuretics

597

7140

2.50

2.29–2.72

1.74

1.60–1.90

 < 0.0001

 TEIC + thiazide diuretics

1

16

1.87

0.25–14.1

1.18

0.15–9.20

0.8721

 Non-target drugs

22,181

661,927

1.00

–

1.00

–

–

Thiazide-like diuretics

 TEIC

147

1622

2.67

2.25–3.16

2.64

2.22–3.14

 < 0.0001

 Thiazide-like diuretics

111

1401

2.33

1.92–2.83

1.59

1.31–1.94

 < 0.0001

 TEIC + thiazide-like diuretics

0

0

–

–

–

–

–

 Non-target drugs

22,667

667,666

1.00

–

1.00

–

–

Potassium-sparing diuretics

 TEIC

134

1522

2.68

2.24–3.19

2.67

2.23–3.20

 < 0.0001

 Potassium-sparing diuretics

1192

13,017

2.78

2.62–2.96

2.13

1.99–2.27

 < 0.0001

 TEIC + potassium-sparing diuretics

13

100

3.95

2.22–7.04

3.62

2.01–6.51

 < 0.0001

 Non-target drugs

21,586

656,050

1.00

–

1.00

–

–

Vaptans

 TEIC

144

1613

2.66

2.24–3.16

2.63

2.21–3.14

 < 0.0001

 Vaptans

429

3107

4.11

3.72–4.56

2.47

2.21–2.75

 < 0.0001

 TEIC + vaptans

3

9

9.93

2.69–36.7

6.34

1.67–24.0

0.0066

 Non-target drugs

22,349

665,960

1.00

–

1.00

–

–

  1. The number of patients with and without AKI in each category was presented. The target drugs were TEIC with intravenous administration and diuretics. A multivariate logistic regression model was used to determine the adjusted ROR by introducing age, sex, reporting year, and co-existing diseases (chronic kidney disease, hypertension, diabetes, cardiac failure, and sepsis).
  2. AKI acute kidney injury, ROR reporting odds ratio, 95% CI 95% confidence interval, TEIC teicoplanin.
Back to article page